Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Axillary lymph nodes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    115 result(s) found for: Axillary lymph nodes. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-004429-25 Sponsor Protocol Number: TS-001-DK Start Date*: 2006-10-31
    Sponsor Name:Viborg Sygehus
    Full Title: A single cohort, open trial to evaluate the efficacy and safety of TachoSil in prevention of seroma formation following axillary lymph node dissection in women following surgery for breast cancer. ...
    Medical condition: Seroma formation in the axilla following axillary dissection of lymphnodes following surgery for breast cancer in women
    Disease: Version SOC Term Classification Code Term Level
    7.1 10040102 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000819-67 Sponsor Protocol Number: MTW_2020_KC01 Start Date*: 2020-07-28
    Sponsor Name:Maidstone and Tunbridge Wells NHS Trust
    Full Title: SENTINUS: Technical feasibility and diagnostic accuracy of intradermal microbubbles and contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following t...
    Medical condition: Breast Cancer - Using SonoVue injected intradermally into the breast and contrast enhanced ultrasound to see if the cancer has spread via lymphatic channels to sentinel lymph nodes in the axilla.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-000393-20 Sponsor Protocol Number: AX-CES1.2020 Start Date*: 2020-10-23
    Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA
    Full Title: USE OF SULFUR HEXAFLUORIDE MICROBUBBLES IN INTRAOPERATIVE SURGICAL EVALUATION OF AXILLARY LYMPH NODES IN LOCO-REGIONAL ANESTHESIA BREAST SURGERY: COMPARISON WITH THE TRADITIONAL METHODICAL. PRELIMI...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005219-98 Sponsor Protocol Number: PH3-01 Start Date*: 2012-10-08
    Sponsor Name:Galena Biopharma, Inc
    Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)
    Medical condition: Operable early-stage, node-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10071113 Node-positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001557-46 Sponsor Protocol Number: 01 Start Date*: 2012-06-27
    Sponsor Name:Sydvestjysk Sygehus, Esbjerg [...]
    1. Sydvestjysk Sygehus, Esbjerg
    2. Odense Universitetshospital
    Full Title: Perioperativ installation of ropivacain in mastectomy – with or without axillary lymph node dissection after sentinel node diagnostics or known lymph node metastasis – A double-blind, randomized cl...
    Medical condition: Unilateral mastectomy with or without axillary lymph node dissection
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000100-41 Sponsor Protocol Number: B-AP-ICG-IV Start Date*: 2013-02-28
    Sponsor Name:Jules Bordet Institute
    Full Title: Histological study of the (intravenously injected) Indocyanine Green (ICG) distribution in tumour bearing breasts and in axillary pieces of dissection
    Medical condition: breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023006-12 Sponsor Protocol Number: 2010-362 Start Date*: 2011-01-14
    Sponsor Name:Professor Krzysztof Tadeusz Drzewiecki
    Full Title: Lipofilling with MSC enriched fat, a permanent autologous filler?
    Medical condition: Patients who have a need of reconstruction after surgery, eg. after mastectomy. The purpose of this clinical trial, is to make a reproducible and safe method for fat transplantation, that can be us...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037773 Radical mastectomy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006181-42 Sponsor Protocol Number: RAD_USPALS_01 Start Date*: 2007-03-15
    Sponsor Name:UMC St Radboud
    Full Title: The use of USPIO enhanced MRI in the assessment of axillary lymph node status in patients with invasive breast cancer
    Medical condition: The presence of axillary metastasis in patients with proven invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004319-29 Sponsor Protocol Number: 20120283 Start Date*: 2013-05-03
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer
    Medical condition: HER2 Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) SK (Completed) IT (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-000549-21 Sponsor Protocol Number: MAGSTAR Start Date*: 2015-03-16
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St. Thomas' NHS Foundation Trust
    Full Title: MAGnetic versus STAndard technique for sentinel node biopsy in breast cancer compared in a Randomised controlled trial
    Medical condition: Many women with breast cancer undergo sentinel lymph node biopsy in order to identify if the breast cancer has spread (metastasis) to the lymph nodes. This study is aimed at evaluating a new magnet...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016743-18 Sponsor Protocol Number: ICG10 Start Date*: 2010-02-02
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Medical condition: Primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005834-19 Sponsor Protocol Number: GBG44 Start Date*: 2007-10-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer
    Medical condition: breast cancer, primary systemic therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003268-19 Sponsor Protocol Number: BR-TUM-ICG-IV-2 Start Date*: 2014-10-06
    Sponsor Name:Jules Bordet Institute
    Full Title: Study evaluating breast cancer tumorectomy guided by Near-Infrared imaging after the intravenous injection of free Indocyanine Green
    Medical condition: Imaging of tumours and their margins after intravenous injection of Indocyanine Green to breast cancer patients
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000114-10 Sponsor Protocol Number: LF-PB/11/04 Start Date*: 2012-10-09
    Sponsor Name:CHEMI S.P.A.
    Full Title: A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast ...
    Medical condition: Patient undergoing breast surgery with axillary lymph node dissection.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005788-28 Sponsor Protocol Number: ICG1 Start Date*: 2014-01-24
    Sponsor Name:Landeskrankenhaus Fedkirch
    Full Title: Influence of Body Mass Index on the identification rate of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Medical condition: A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004822-19 Sponsor Protocol Number: ICORG 05-11/NSABP B-38 Start Date*: 2006-02-15
    Sponsor Name:ICORG the all Ireland Co-operative Oncology Research Group
    Full Title: A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphami...
    Medical condition: Early stage node positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001974-10 Sponsor Protocol Number: CA184-029 Start Date*: 2009-03-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORT...
    Medical condition: High Risk Stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) SE (Completed) FI (Completed) CZ (Completed) DK (Completed) DE (Completed) ES (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001555-12 Sponsor Protocol Number: SLNBI Start Date*: 2013-08-09
    Sponsor Name:Jules Bordet Institute
    Full Title: Evaluation of Near-Infra-Red Imaging after peri-areolar and subcutaneous injections of ICG in comparison with the lymphoscintigraphic technique using intra-mammary and peri-tumoral injection of 99m...
    Medical condition: Determination of the detection rate, false negative rate and overall accuracy of the sentinel lymph nodes approach using subcutaneous and peri-areolar injections of ICG for breast cancer patients.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004263-35 Sponsor Protocol Number: CFEM345D2411 Start Date*: 2006-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer
    Medical condition: This study will be a head to head comparison of letrozole versus anastrozole in the adjuvant treatment of high risk patients. Post-menopausal patients who recently have undergone their primary surg...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 13:46:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA